HALOZYME THERAPEUTICS, INC. Contract Liability (Deferred Revenue)
HALOZYME THERAPEUTICS, INC. (HALO) had Contract Liability (Deferred Revenue) of $667.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-06.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-11-06
- 2023-09-30: Contract with Customer, Liability, Current $667.00K.
- 2023-06-30: Contract with Customer, Liability, Current $842.00K.
- 2022-12-31: Contract with Customer, Liability, Current $3.25M.
- 2021-12-31: Contract with Customer, Liability, Current $1.75M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-09-30 | $667.00K 10-Q · filed 2023-11-06 |
| 2023-06-30 | $842.00K 10-Q · filed 2023-08-08 |
| 2022-12-31 | $3.25M 10-Q · filed 2023-11-06 |
| 2021-12-31 | $1.75M 10-K · filed 2023-02-21 |
| 2020-12-31 | $1.75M 10-K · filed 2022-02-22 |
| 2020-09-30 | $748.00K 10-Q · filed 2020-11-02 |
| 2020-06-30 | $748.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $4.01M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $4.01M 10-K · filed 2021-02-23 |
| 2019-09-30 | $3.51M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $6.51M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $4.25M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $4.25M 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |